Axsome Therapeutics, Inc. $AXSM Shares Purchased by DNB Asset Management AS

DNB Asset Management AS lifted its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 33.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 101,981 shares of the company’s stock after purchasing an additional 25,339 shares during the period. DNB Asset Management AS’s holdings in Axsome Therapeutics were worth $12,386,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Axsome Therapeutics by 6.0% during the third quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock valued at $507,739,000 after buying an additional 235,626 shares during the period. Geode Capital Management LLC lifted its position in shares of Axsome Therapeutics by 5.8% in the second quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock worth $103,303,000 after purchasing an additional 54,600 shares in the last quarter. State Street Corp boosted its holdings in shares of Axsome Therapeutics by 5.8% during the second quarter. State Street Corp now owns 958,503 shares of the company’s stock worth $100,058,000 after purchasing an additional 52,483 shares during the period. Bank of America Corp DE grew its position in Axsome Therapeutics by 41.1% during the second quarter. Bank of America Corp DE now owns 753,429 shares of the company’s stock valued at $78,650,000 after purchasing an additional 219,527 shares in the last quarter. Finally, Man Group plc increased its stake in Axsome Therapeutics by 2.3% in the 2nd quarter. Man Group plc now owns 525,069 shares of the company’s stock valued at $54,812,000 after buying an additional 11,848 shares during the period. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Activity

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 78,703 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $171.28, for a total value of $13,480,249.84. Following the completion of the sale, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,238,183.12. This represents a 91.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Mark L. Jacobson sold 35,378 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $161.88, for a total transaction of $5,726,990.64. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 369,252 shares of company stock worth $61,145,545. Corporate insiders own 22.30% of the company’s stock.

Analysts Set New Price Targets

AXSM has been the subject of a number of research reports. Piper Sandler lifted their target price on shares of Axsome Therapeutics from $148.00 to $223.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Robert W. Baird set a $209.00 target price on Axsome Therapeutics in a research note on Tuesday, January 13th. Morgan Stanley set a $207.00 price target on Axsome Therapeutics in a report on Tuesday. Jefferies Financial Group set a $215.00 price objective on shares of Axsome Therapeutics in a research report on Monday, February 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 21st. Seventeen analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $216.12.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $260 price target and forecasts a large rebound into FY‑2027 (FY‑2027 EPS of $11.87 with strong quarterly ramps). This upbeat long‑term view supports investor optimism. Read More.
• Positive Sentiment: Recent company results showed a Q4 EPS beat and revenue up ~65% year‑over‑year, which provides fundamental support for the stock despite near‑term model revisions. Read More.
• Neutral Sentiment: Reported short interest data in late February shows effectively zero shares short (the published figures contain anomalies/NaN), so short‑position dynamics appear minimal and unlikely to be a near‑term driver. Read More.
• Negative Sentiment: HC Wainwright trimmed multiple near‑term 2026 estimates (Q1‑Q3 and FY‑2026 materially lowered; Q4‑2026 also revised down from prior forecasts). These cuts signal more modest near‑term profitability than previously expected and increase uncertainty for 2026 results. Read More.

Axsome Therapeutics Trading Up 0.4%

Shares of NASDAQ:AXSM opened at $163.89 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.50 and a current ratio of 1.55. The stock’s 50-day moving average is $175.78 and its 200-day moving average is $146.35. The company has a market cap of $8.38 billion, a P/E ratio of -44.41 and a beta of 0.40. Axsome Therapeutics, Inc. has a 52-week low of $86.99 and a 52-week high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.14. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.The firm had revenue of $196.00 million for the quarter, compared to analyst estimates of $191.33 million. The business’s revenue for the quarter was up 65.0% compared to the same quarter last year. Equities research analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.